Bristol Myers Squibb Anticipates Significant Decline In Sales In The US For Clopidogrel
GenericsWeb, the leader in established pharmaceutical patent analysis and searching, recently published an article based on its proprietary Pipeline Patent Intelligence that analyses opportunities in launching generic versions of Sanofi and Bristol Myers Squibb’s blockbuster platelet aggregation inhibitor Clopidogrel (Plavix® and Isocover®). US sales increased by 8% in 2011, generating US$6.62 billion of the US$7.09 billion gained globally; resulting in a global sale increase of 6%. Sales in non-US markets declined 9%. (PRWEB) May 17, 2012 The article by GenericsWeb highlights th
Contributor
About
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
PRWeb, a leader in online news and press release distribution, has been used by attorneys, law firms and more than 40,000 organizations
Categories
- Articles 313
- Bankruptcy 44
- Business 135
- Cases & Codes 68
- Contracts 27
- Criminal Law 122
- Employment 24
- Expert Reports 3
- Expert Witness 34
- Family Law 58
- Form Letters 15
- Immigration 3
- Intellectual Prop 32
- Internet Law 10
- Law Practice 99
- Law School 2
- Legal Research 19
- Litigation 186
- Miscellaneous 64
- PR Web 41689
- Personal Injury 609
- Press Release 43
- Probate 54
- Real Estate 68
- Tax Law 23
- Workers Comp 4